Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2026-01-09 @ 12:59 AM
Study NCT ID:
NCT03070093
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2021-04-20
First Post:
2017-02-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Sponsor:
Astellas Pharma Global Development, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2017-02-28
First Submit QC Date:
None
Study First Post Date:
2017-03-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-04-18
Last Update Post Date:
2021-04-20
Last Update Post Date Type:
ACTUAL